Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Cajal Neuroscience is a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to discover novel targets and therapeutics for neurodegeneration. The company combines a suite of state-of-the-art approaches and technologies, including integrative human genetics and multi-omics, high-throughput functional genomics, and advanced microscopy, to accelerate neurodegeneration target and drug discovery.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 29, 2022 | Series A | $96M | 7 | Lux Capital The Column Group | — | Detail |
Jan 1, 2020 | Seed | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lux Capital | Yes | Series A |
The Column Group | Yes | Series A |
Alexandria Venture Investments | — | Series A |
Bristol Myers Squibb | — | Series A |
Dolby Family Ventures | — | Series A |
Evotec | — | Series A |
Two Sigma Ventures | — | Series A |